Bank Of America Corp Aeglea Bio Therapeutics, Inc. Transaction History

Bank Of America Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$0.29 - $0.61 $5,643 - $11,870	19,460 Added 123.4%	35,230 $10,000
Q4 2022 Feb 10, 2023	BUY	$0.35 - $1.54 $1,432 - $6,304	4,094 Added 35.06%	15,770 $7,000
Q3 2022 Nov 14, 2022	BUY	$0.38 - $0.81 $1,662 - $3,543	4,375 Added 59.92%	11,676 $6,000
Q2 2022 Aug 12, 2022	SELL	$0.5 - $2.66 $5,352 - $28,472	-10,704 Reduced 59.45%	7,301 $3,000
Q1 2022 May 16, 2022	SELL	$1.87 - $4.77 $24,425 - $62,305	-13,062 Reduced 42.04%	18,005 $41,000
Q4 2021 Feb 08, 2022	BUY	$3.5 - $8.42 $18,998 - $45,703	5,428 Added 21.17%	31,067 $147,000
Q3 2021 Nov 15, 2021	BUY	$6.03 - $7.95 $32,700 - $43,112	5,423 Added 26.83%	25,639 $204,000
Q2 2021 Sep 13, 2021	BUY	$6.32 - $8.38 $127,765 - $169,410	20,216 New	20,216 $141,000

241K

Ticker AGLE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,172,500
Market Cap $1.69B
Description
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.